Möchten Sie immer auf dem neuesten Stand bleiben?

At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which will this year take part in Istanbul, Türkiye from 12 to 15 June 2026, the Danish pharmaceutical company...

EAACI, together with AEPNAA, SEAIC, and SEICAP, has called for urgent action to improve the safety of children at risk of anaphylaxis in schools.

Today, ALK announced that children aged 4 and older living with severe allergies across the EU can now access the first and only needle-free adrenaline treatment for anaphylaxis, after the European...

ALK presents new findings that directly compare user preference between needle-free nasal and injectable adrenaline treatments for anaphylaxis.

TEMECULA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- ODRescue™, a program of FFF Enterprises, Inc. — the nation’s most trusted specialty drug distributor and diversified healthcare company — today...

Washington, DC, Aug. 27, 2025 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) announces the availability of the first validated food allergy anaphylaxis action plan,...

Life-threatening allergies may be triggered by respiratory virus vaccines, such as influenza and COVID. Repeated doses may sensitize patients.

Richmond, Virginia, May 15, 2025 (GLOBE NEWSWIRE) -- New findings from a retrospective analysis of U.S. commercial claims data indicate that patients prescribed AUVI-Q® (epinephrine injection, USP)...

ATHENS, Greece, Dec. 12, 2024 (GLOBE NEWSWIRE) -- FAAM-EUROBAT 2024, held from 21-23 November at the InterContinental Athenaeum Athens, brought over 550 attendees from over 25 countries to share...

On 21 November 2024, during the opening day of EAACI FAAM-EUROBAT 2024 in Athens, Greece, EAACI proudly launches World Anaphylaxis Day. Join us!